CTOs on the Move

Indiana Hemophilia and Thrombosis Center

www.ihtc.org

 
The Indiana Hemophilia & Thrombosis Center (IHTC) is the only federally recognized comprehensive hemophilia treatment center in Indiana and one of the largest centers in the nation. The IHTC is a 501(c)3 nonprofit entity that is dedicated to providing the best, most comprehensive care to people in Indiana with bleeding or clotting disorders and to their families. The IHTC is both nationally and internationally distinguished as a Center of Excellence for its leadership in bleeding disorder patient care, education and research.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ihtc.org
  • 8326 Naab Road
    Indianapolis, IN USA 46260
  • Phone: 317.871.0000

Executives

Name Title Contact Details
Sherry Slick
 Chief Information Officer Profile

Similar Companies

Jefferson Medical

Jefferson Medical is a Oak Ridge, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SwedishAmerican Health System

SwedishAmerican Health System is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. SwedishAmerican Health System is based in Rockford, IL. You can find more information on SwedishAmerican Health System at www.swedishamerican.org

Access Lifts and Ramps

Access Lifts and Ramps is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hudson Health Plan

Hudson Health Plan is a Tarrytown, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.